Goldman Sachs analyst Corinne Jenkins lowered the firm’s price target on Halozyme (HALO) to $45 from $46 and keeps a Neutral rating on the shares. The firm is adjusting its model after Argenx (ARGX) reported that the drug arm of its Phase 3 ADDRESS study of Vyvgart Hytrulo in pemphigus vulgaris failed to show a statistically significant improvement on the primary endpoint of complete remission on a minimal dose of steroids, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- Halozyme’s Vyvgart SC receives European Commission approval
- Halozyme price target lowered to $46 from $48 at Piper Sandler
- HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
- Halozyme raises FY23 adjusted EPS view to $2.70-$2.80 from $2.65-$2.75
- Halozyme reports Q3 adjusted EPS 75c, consensus 73c
